ReviewCNS neuroscience & therapeutics2016
Cysteinyl Leukotrienes and Their Receptors: Emerging Therapeutic Targets in Central Nervous System Disorders.
Review in CNS neuroscience & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 78 citations in OpenAlex.
- Montelukast Ameliorates Antimony-Induced Neurotoxicity Accompanied by Alterations in Oxidative Stress, Neuroinflammation, and Mitochondrial Function.Biological trace element research · 2026Article
- Zafirlukast Exacerbates Behavioral Seizure Activity and Blood-Brain Barrier Disruption Despite Modestly Reducing Neuronal Injury Markers in a PTZ-Induced Early Epileptogenesis Mouse Model.Molecular neurobiology · 2026Article
- Montelukast attenuated memory decline, neuroinflammatory and neurodegenerative biomarkers in AβPsychopharmacology · 2026Article
- Comparative analysis of adverse drug reaction reports for leukotriene receptor antagonists mainly indicated for allergic rhinitis and asthma: a WHO VigiAccess study.Frontiers in medicine · 2026Article
- Molecular insights into ago-allosteric modulation at cysteinyl leukotriene receptor 2.Nature communications · 2025Article
- The role of arachidonic acid metabolites in major depressive disorder: mechanisms and therapeutic implications.Metabolic brain disease · 2025Review
- Montelukast alleviates thioacetamide-induced hepatic encephalopathy in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- CysLTJournal of neurochemistry · 2025Article
- Montelukast Improves Urinary Bladder Function After Complete Spinal Cord Injury in Rats.International journal of molecular sciences · 2025Article
- Structural basis of the cysteinyl leukotriene receptor type 2 activation by LTD4.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Leukotriene signaling in neurodegeneration: implications for treatment strategies.Inflammopharmacology · 2024Review
- Disease phenotypic screening in neuron-glia cocultures identifies blockers of inflammatory neurodegeneration.iScience · 2024Article
- Leukotriene A4 hydrolase inhibition improves age-related cognitive decline via modulation of synaptic function.Science advances · 2023Article
- Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy.Biomolecules · 2023Review
- Multifaceted Nature of Lipid Droplets in Viral Interactions and Pathogenesis.Microorganisms · 2023Review
- G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.Signal transduction and targeted therapy · 2023Review
- Exploring the neuroprotective effects of montelukast on brain inflammation and metabolism in a rat model of quinolinic acid-induced striatal neurotoxicity.Journal of neuroinflammation · 2023Article
- Alzheimer's disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?Frontiers in pharmacology · 2023Review
- The Role of Ferroptosis in Blood-Brain Barrier Injury.Cellular and molecular neurobiology · 2023Review
- Gene expression profile suggests different mechanisms underlying sporadic and familial mesial temporal lobe epilepsy.Experimental biology and medicine (Maywood, N.J.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cysteinyl leukotrienes are a group of the inflammatory lipid molecules well known as mediators of inflammatory signaling in the allergic diseases. Although they are traditionally known for their role in allergic asthma, allergic rhinitis, and others, recent advances in the field of biomedical research highlighted the role of these inflammatory mediators in a broader range of diseases such as in the inflammation associated with the central nervous system (CNS) disorders, vascular inflammation (atherosclerotic), and in cancer. Among the CNS diseases, they, along with their synthesis precursor enzyme 5-lipoxygenase and their receptors, have been shown to be associated with brain injury, Multiple sclerosis, Alzheimer's disease, Parkinson's disease, brain ischemia, epilepsy, and others. However, a lot more remains elusive as the research in these areas is emerging and only a little has been discovered. Herein, through this review, we first provided a general up-to-date information on the synthesis pathway and the receptors for the molecules. Next, we summarized the current findings on their role in the brain disorders, with an insight given to the future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.